Adicet Bio Reports Q3 GAAP EPS Miss of $0.17
Adicet Bio (ACET) reported third-quarter financial results featuring a GAAP earnings per share (EPS) of -$1.76, missing analyst expectations by $0.17. The report highlights the ongoing costs associated with the company's clinical development stage. As of September 30, 2026, the company held $100.9 million in cash, cash equivalents, and short-term investments. Management indicated that these current liquid assets are expected to be sufficient to support their ongoing operations for the foreseeable future.
Tickers: $ACET